Ghost Tree Capital Upped Its Portola Pharmaceuticals (Put) (PTLA) Holding; Abaxis (ABAX)’s Sentiment Is 1.12

December 7, 2017 - By Winifred Garcia

Ghost Tree Capital Llc increased Portola Pharmaceuticals Inc (Put) (PTLA) stake by 100% reported in 2017Q2 SEC filing. Ghost Tree Capital Llc acquired 200,000 shares as Portola Pharmaceuticals Inc (Put) (PTLA)’s stock rose 22.73%. The Ghost Tree Capital Llc holds 400,000 shares with $22.47 million value, up from 200,000 last quarter. Portola Pharmaceuticals Inc (Put) now has $3.45B valuation. The stock increased 3.45% or $1.76 during the last trading session, reaching $52.81. About 334,098 shares traded. Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) has risen 51.17% since December 7, 2016 and is uptrending. It has outperformed by 34.47% the S&P500.

Abaxis, Inc. develops, manufactures, markets, and sells portable blood analysis systems for use in human or veterinary patient care settings to provide rapid blood constituent measurements for clinicians worldwide. The company has market cap of $1.07 billion. It operates in two divisions, Medical Market and Veterinary Market. It has a 39.42 P/E ratio. The firm offers Piccolo chemistry analyzers with rapid blood constituent measurements for use in human patient care; and Piccolo profiles that are single-use medical reagents.

Investors sentiment decreased to 1.31 in 2017 Q2. Its down 0.29, from 1.6 in 2017Q1. It is negative, as 17 investors sold PTLA shares while 58 reduced holdings. 45 funds opened positions while 53 raised stakes. 48.64 million shares or 0.79% more from 48.26 million shares in 2017Q1 were reported. Dekabank Deutsche Girozentrale holds 0.01% of its portfolio in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) for 28,400 shares. Temasek Holding (Private) stated it has 4.88 million shares or 1.77% of all its holdings. Employees Retirement Association Of Colorado holds 0% in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) or 12,033 shares. Airain Limited holds 0.03% or 13,643 shares in its portfolio. Tortoise Inv Ltd Llc has 164 shares. Hanseatic Mngmt Svcs reported 22,800 shares or 0.65% of all its holdings. Valley Advisers has invested 0.03% of its portfolio in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). Victory has invested 0% in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). Deutsche Bank & Trust Ag reported 626,798 shares. Paradigm Asset accumulated 0% or 11,800 shares. Gotham Asset Mngmt Ltd Liability Corporation invested in 23,898 shares. 1,016 are held by First Personal Ser. Eam Invsts Limited has 0.6% invested in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) for 64,361 shares. Raymond James Svcs Advsrs has 0% invested in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) for 4,408 shares. Credit Suisse Ag reported 107,945 shares.

Among 6 analysts covering Portola Pharmaceuticals (NASDAQ:PTLA), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Portola Pharmaceuticals had 29 analyst reports since August 5, 2015 according to SRatingsIntel. The firm has “Overweight” rating given on Friday, October 6 by Morgan Stanley. The stock of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) has “Hold” rating given on Thursday, August 10 by Credit Suisse. The firm has “Buy” rating by Oppenheimer given on Friday, August 4. Goldman Sachs initiated the stock with “Buy” rating in Friday, December 18 report. Citigroup upgraded the stock to “Buy” rating in Tuesday, January 3 report. The firm has “Buy” rating given on Monday, June 26 by Oppenheimer. The company was maintained on Monday, June 26 by Citigroup. The stock of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) has “Neutral” rating given on Friday, August 19 by Credit Suisse. The firm earned “Buy” rating on Thursday, August 10 by Oppenheimer. The stock of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) earned “Buy” rating by Cowen & Co on Wednesday, August 9.

Ghost Tree Capital Llc decreased Enanta Pharmaceuticals Inc (NASDAQ:ENTA) stake by 100,000 shares to 200,000 valued at $7.20M in 2017Q2. It also reduced Puma Biotechnology Inc (NYSE:PBYI) stake by 75,000 shares and now owns 150,000 shares. Blueprint Medicines Corp was reduced too.

Ratings analysis reveals 0 of Abaxis’s analysts are positive. Out of 2 Wall Street analysts rating Abaxis, 0 give it “Buy”, 0 “Sell” rating, while 2 recommend “Hold”. ABAX was included in 2 notes of analysts from November 30, 2016. As per Friday, January 27, the company rating was maintained by Stifel Nicolaus. Northcoast downgraded Abaxis, Inc. (NASDAQ:ABAX) on Wednesday, November 30 to “Neutral” rating.

The stock decreased 2.73% or $1.315 during the last trading session, reaching $46.915. About 79,495 shares traded. Abaxis, Inc. (ABAX) has risen 7.18% since December 7, 2016 and is uptrending. It has underperformed by 9.52% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: